<PAGE>

                                                                    Exhibit 10.1

            TECHNOLOGY TESTING AND CONTINGENT PURCHASE AGREEMENT FOR
                                    BIOSENTRY

      This Agreement is entered into by and between KIMPEN, S.A. DE C.V. (the
"Company") and JMAR Technologies, Inc., a Delaware corporation operating in the
State of California (hereinafter "JMAR").

                                 R-E-C-I-T-A-L-S

      1. Kimpen is responsible for the quality of the beverages produced by
Bepensa and desires to have a system to monitor for the presence of a variety of
microorganisms in water prior to being processed into a particular beverage;

      2. JMAR is a leading innovator in the development of laser-based equipment
for imaging, analysis and fabrication and has developed the BioSentry(TM)
system, a laser-based, early-warning system for detecting and classifying
potentially harmful microorganisms in water supplies;

      3. JMAR has successfully completed a proof of concept and beta versions of
its BioSentry(TM) units, and has offered to install 1 beta BioSentry unit in the
Company's facilities for the purposes of testing the operation of the beta unit
in a water facility environment on the terms and conditions set forth herein;
and

      4. JMAR and the Company desire to engage in a joint effort to test the
operation and effectiveness of the BioSentry units. If successful, the Company
has agreed to purchase at least 2 production units of the BioSentry(TM) system
for factory testing and an additional 15 production units upon successful
completion of the factory test on the terms set forth herein.

                                C-O-V-E-N-A-N-T-S

      1. Services to Be Performed. JMAR agrees to install one BioSentry beta
unit at the Company's laboratory facility and to operate and perform testing of
such unit in accordance with the BioSentry Test Program Proposal and Test Plan
attached hereto as Exhibit A and Exhibit A-1 and incorporated herein by
reference. All work performed by JMAR shall be subject to review and

                                        1
<PAGE>

approval by the Company. The Company shall have no obligation to approve any
work found defective by the Company, in its sole discretion.

      2. Installation and Testing of Beta Units. JMAR agrees to a) supply and
install one BioSentry(TM) Beta unit(s) at the Company's laboratory facility and
b) operate and test the Beta units in accordance with Exhibit A. The Company
agrees to make available its facility to JMAR at no additional cost to JMAR for
the purpose of the installation and testing of one BioSentry(TM) Beta unit(s).
The Company also agrees to make its personnel available to JMAR at the Company's
cost to support the installation and testing of the Beta units in accordance
with Exhibit A.

      3. Contingent Purchase Order. Upon successful completion of the Test Plan
for the Beta unit installed in the laboratory as set forth in Exhibit A-1, the
Company will issue a binding Purchase Order obligating the Company to purchase
at least 2 production units of the BioSentry(TM) system. The two production
units will be installed in factory locations and operated and tested in
accordance with the Test Plan set forth in Exhibit A-1. Upon successful
completion of the Test Plan for these two production units, the Company will
issue a binding Purchase Order obligating the Company to purchase an additional
15 production units for delivery within 6 months after the completion of the
factory tests. The Purchase Orders will contain the terms and conditions set
forth in the Quotation attached hereto as Exhibit B and incorporated herein by
reference.

      4. Work Performance Standards. JMAR agrees to perform all work and
services required by this Agreement in a manner which complies with all
applicable health and safety standards and in a manner which avoids damage or
injury to any real or personal property of any person or entity, including any
real or personal property of the Company. JMAR agrees to perform the work at all
times in a manner which avoids the creation of any trespass or private or public
nuisance during conduct of the work.

      5. Liability for Work of Agents, Independent Contractors, and
Subcontractors. JMAR shall be solely liable and responsible for all labor and
materials provided by any agent, employee, subcontractor, supplier, or
independent contractor hired or retained by JMAR to perform any work or to
provide any materials or supplies. Except as provided in this Agreement, the
Company shall have no liability whatsoever for any work or services performed or
any materials or supplies provided by JMAR or its agents, employees,
subcontractors, suppliers, or independent contractors.

                                        2
<PAGE>

      6. Time for Completion of Services. As a material term of this Agreement,
JMAR agrees to complete all work and services associated with the Laboratory
Test Plan required by this Agreement by no later than August 15, 2005, subject
to extension upon the mutual written agreement of the parties. Future testing of
two production BioSentry(TM) Systems at two Bepensa factories will be scheduled
following the completion of the Laboratory Test Plan.

      7. Termination Right. Either party shall have the express right to
terminate this Agreement at any time by giving thirty (30) consecutive days
advance written notice to the other party upon the failure of the BioSentry Beta
unit(s) to perform in accordance with the Test Plan set forth in Exhibit A-1 for
a period of 60 days after installation. Upon receipt of such a termination
notice, JMAR shall promptly cease its testing and operation of the BioSentry
units, shall remove the BioSentry units from the Company's facilities within 30
days at its sole cost and expense and shall avoid any injury or damage to any
part of the Company's facilities in removing the units. The Company shall be
responsible for restoring the premises to its previous condition.

      8. Independent Contractor. As a material term of this Agreement, it is
expressly agreed between the parties that JMAR is performing all work and
services for the Company pursuant to this Agreement as an independent contractor
and not as an agent or employee of the Company. The parties further agree and
acknowledge that the Company expects JMAR to make its own independent
determination of the means and methods to perform all work required by this
Agreement, and will not be directed as to any of these means or methods by the
Company.

      9. Insurance. At all times during the term of this Agreement, JMAR shall
maintain workers compensation insurance and a commercial general liability
insurance policy in amounts that are customary for businesses of this nature.

      10. Job Site Safety. JMAR shall be solely liable and responsible for the
job site safety and compliance with all applicable laws, rules and regulations
pertaining to job safety for all agents, employees, subcontractors, suppliers,
and independent contractors retained by JMAR to perform any work or services or
to provide any materials required by this Agreement. However, JMAR shall not be
liable or responsible for job site safety for any workers or agents employed by
the Company in connection with the installation and operation of the BioSentry
units.

                                        3
<PAGE>

      11. Indemnity. As a material term of this Agreement, JMAR agrees to hold
harmless, indemnify, and defend the Company and its directors, officers,
employees, agents, and representatives from and against any and all liability,
claims, causes of action, suits, actions, damages, losses, costs, fees,
expenses, fines, and penalties, of whatever type or nature, including all costs
of defense and attorney fees, caused in whole or in part, or claimed to be
caused in whole or in part by the action, inaction, passive or active
negligence, or intentional misconduct of JMAR or its directors, officers,
employees, agents, subcontractors, sub-consultants, suppliers, or independent
contractors, except claims and causes of action caused by the negligence or
intentional misconduct of the Company or its directors, officers, employees or
agents. The Company agrees to hold harmless, indemnify, and defend JMAR and its
directors, officers, employees, agents, and representatives from and against any
and all claims, causes of action, suits, actions, damages, losses, costs, fees,
expenses, fines, and penalties, of whatever type or nature, including all costs
of defense and attorney fees, caused by the negligence or intentional misconduct
of the Company or its directors, officers, employees, agents, subcontractors,
sub-consultants, suppliers, or independent contractors. In the event that any
administrative proceeding, litigation or arbitration is instituted naming an
indemnified party as a defendant, the indemnified party shall be entitled to
appoint its own independent counsel to represent it, and the indemnifying party
agrees to pay all reasonable attorneys fees, expert fees and costs, and
litigation costs associated with this defense within thirty (30) days of any
billing.

      12. Miscellaneous Provisions.

            12.1 California Law Governs. The rights and obligations of the
parties under this Agreement shall be governed and determined according to the
substantive laws of the State of California (excluding the conflict of laws
principles thereof. This Agreement shall be deemed to have been entered into at
Carlsbad, California, regardless of the places of signing by the parties hereto
or the order of their signing.

            12.2 Dispute Resolution. Any controversy or claim arising out of or
relating to this Agreement or the breach thereof, shall be settled by
arbitration at San Diego, California, in accordance with the Commercial
Arbitration Rules of the American Arbitration Association, and judgment upon the
award of the arbitrator(s) shall be entered in any court with appropriate
jurisdiction as the final binding judgment. The arbitrators shall not be
permitted to award punitive or other exemplary damages as a part of such award.
In addition to any other relief as may be granted,

                                        4
<PAGE>

the prevailing party shall be entitled to reasonable attorneys' fees in such
arbitration, with the amount thereof to be determined by the arbitrator or the
court.

            12.3 Modification. This Agreement may not be modified, amended,
rescinded, canceled, or waived, in whole or in part, except in writing signed by
the parties hereto.

            12.4 Entire Agreement. This Agreement constitutes the entire
agreement of the parties with respect to the subject matter hereof, and
supersedes all previous agreements by and between JMAR and the Company, as well
as all proposals, oral or written, and all negotiations, conversations or
discussions heretofore had between the parties related to this Agreement.

The parties mutually declare that this Agreement and its exhibits constitute a
final, complete and integrated agreement between the parties.

            12.5 Prohibition on Assignment. Except as otherwise provided herein,
neither party shall have the right to assign or otherwise transfer its rights
and obligations under this Agreement (whether by contract, merger,
consolidation, sale of stock or assets or otherwise) except with the prior
written consent of the other party. Any prohibited assignment shall be null and
void.

            12.6 Binding Effect. This Agreement shall inure to the benefit of
and be binding upon the parties and on their respective purchasers, successors,
heirs and assigns.

            12.7 Unenforceable Provisions. In the event that any of the terms of
this Agreement are in conflict with any rule of law or statutory provisions or
are otherwise unenforceable under the laws or regulations of any government or
subdivision thereof, such terms shall be deemed stricken from the this
Agreement, but such invalidity or unenforceable shall not invalidate any of the
other terms of this Agreement and this Agreement shall continue in force, unless
the invalidity or enforceability of any such provisions hereof does substantial
violence to, or where the invalid or unenforceable provisions comprise an
integral part of, or are otherwise inseparable from, the remainder of this
Agreement.

            12.8 Representation of Capacity to Contract. Each party to this
Agreement represents and warrants that he or she has the authority to execute
this Agreement on behalf of the entity represented by that individual. This
representation is a material term of this Agreement.

                                        5
<PAGE>

            12.9 Opportunity to be Represented by Independent Counsel. Each of
the parties to this Agreement warrants and represents that it has been advised
to consult independent counsel of its own choosing and has had a reasonable
opportunity to do so prior to executing this Agreement.

            12.10 No Waiver. The failure of either party to enforce any term,
covenant or condition of this Agreement on the date it is to be performed shall
not be construed as a waiver of that party's right to enforce this, or any
other, term, covenant, or condition of this Agreement at any later date or as a
waiver of any term, covenant, or condition of this Agreement. No waiver shall
occur unless the waiver is expressly stated in writing and signed by the person
for the party having the authority to expressly waive the benefit or provision,
in writing. No oral waivers shall be effective against either party.

            12.11 No Joint Venture and No Third Party Beneficiaries. Nothing in
this Agreement is intended to create a joint venture, partnership or common
enterprise relationship of any kind between the Company and JMAR. No third
parties shall be construed as beneficiaries of any term, covenant or provision
of this Agreement.

            12.12 Notices. All letters, statements, or notices required pursuant
to this Agreement shall be deemed effective upon receipt when personally served,
transmitted by facsimile machine, or sent certified mail, return receipt
requested, to the following addresses or facsimile numbers:

To: "JMAR"

JMAR Technologies, Inc.
Attention: General Counsel
5800 Armada Drive
Carlsbad, California 92008
Facsimile No. (760) 602-3299

To: "Company"

KIMPEN, S.A. DE C.V.
Calle 31 s/n, Tablaje Catastral 19097
por 30 y Anillo Periferico. Colonia Pacabtun.
C.P. 97160. Merida, Yucatan, Mexico.
Attention: Mr. Adolfo Herrera Hiza

                                        6
<PAGE>

            12.13 Counterparts. This Agreement may be executed in two or more
counterparts, and each such counterpart shall be deemed an original hereof. In
case of any conflict between the English version and any translated version of
this Agreement, the English version shall govern.

            12.14 Effective Date. The effective date of this Agreement executed
in Carlsbad, California, within the North County Judicial Company, County of San
Diego, State of California, is April 15, 2005.

Dated: April 13, 2005                            KIMPEN, S.A. DE C.V.

                                                 By: /s/ ADOLFO HERRERA HIZA
                                                      Mr. Adolfo Herrera Hiza,
                                                      General Manager

Dated: April 13, 2005                            JMAR TECHNOLOGIES, INC.

                                                 By: /s/ JOHN P. RICARDI
                                                      John P. Ricardi,
                                                      Vice President, Senor
                                                      Products Group

                                        7
<PAGE>

                                    EXHIBIT A

                      BIOSENTRY(TM) TEST PROGRAM FOR KIMPEN

1. PROGRAM GOALS

      JMAR's goals in undertaking the Test Program include:

      1.1.  Validate BioSentry(TM) performance for detection and classification
            of Bacteria (E.coli, Pseudomonas,Salmonella & Shigella) and Protozoa
            (Cryptosporidium & Giardia) in accordance with the Test Plan in
            Exhibit A-1.

      1.2.  Demonstrate the value of the BioSentry(TM) to Kimpen

      1.3.  Gain valuable field experience that may result in modifications to
            the BioSentry(TM) prior to production start-up.

      1.4.  Publish joint reports regarding the BioSentry(TM) performance that
            could aide in proliferation of the BioSentry(TM) to the industry.

2. PROGRAM METHODOLOGY

      Create a 2-month test plan that:

      2.1.  Upon successful completion, satisfies Kimpen expectations of the
            BioSentry and results in the sale of at least two BioSentry(TM)
            systems.

      2.2.  Tests the suitability of the BioSentry(TM) as a quality and/or
            security device to ensure Kimpen's water at the test location is
            within the Kimpen's acceptable level of bioburden(1) contamination

      2.3.  Places one BioSentry(TM) Beta unit(s) at mutually agreeable a Kimpen
            location to continuously monitor treated (filtered and disinfected)
            water for Bacteria & Protozoa.

      2.4.  Operates the BioSentry(TM) on a 24/7 basis to continuously monitor
            the Kimpen's water supply and reports any `events' to the Kimpen.

      2.5.  Spikes the BioSentry(TM) weekly with known concentration levels of
            polystyrene test spheres and/or inactivated Bacteria and Protozoa to
            verify the system is working properly

      2.6.  Records BioSentry(TM) operational downtime to measure the system's
            reliability

      2.7.  Completes the Program within 2 months after installation and
            evaluates the performance of the BioSentry(TM) in accordance with
            the test plan detailed in Exhibit A-1

---------------
(1) POPULATION OF VIABLE MICROORGANISMS ON A PRODUCT AND/OR PACKAGE.

                                        8
<PAGE>

3. PROGRAM DETAILS

      3.1.  JMAR RESPONSIBILITIES:

            3.1.1.      Identify a Project Manager to interface with Kimpen.

            3.1.2.      Provide 1 BioSentry(TM) Beta system to Kimpen to be
                        installed at a mutually agreeable location.

            3.1.3.      Integrate the BioSentry(TM) systems with Kimpen's
                        internet or communications network to allow JMAR to
                        monitor the performance of the BioSentry(TM) systems.

            3.1.4.      Provide on-site service and maintenance, as required,
                        for the duration of the program

            3.1.5.      Validate test results through a certified test lab using
                        known test criteria (e.g. EPA Method 1623 for testing of
                        Cryptosporidium)

      3.2.  KIMPEN RESPONSIBILITIES:

            3.2.1.      Provide single Project Manager to interface with JMAR.

            3.2.2.      Make its facilities and personnel available for
                        installation, operation, testing and maintenance of the
                        BioSentry systems.

            3.2.3.      Provide personnel to be trained during the 2-month test
                        period to operate maintain and service the BioSentry(TM)
                        systems.

            3.2.4.      Provide JMAR with sufficient information and/or
                        personnel to help integrate the BioSentry(TM) with
                        Kimpen's internet or communications network.

            3.2.5.      Support monthly meetings of no more than 2 hours with
                        JMAR personnel to review system performance and critique
                        BioSentry(TM) data and system operations.

            3.2.6.      Together with JMAR, publish a report regarding the
                        performance of the BioSentry(TM) at the completion of
                        the Test Program that is suitable for possible public
                        dissemination.

4. SCHEDULE:

      4.1.  1 BioSentry(TM) unit(s) will be ready for installation at the Kimpen
            facility by no later than May 15, 2005.

      4.2.  JMAR will complete installation and integration of the 1
            BioSentry(TM) Beta unit(s) into the Kimpen facility by May 31, 2005.

                                        9
<PAGE>

5. INSTALLATION

    THE BIOSENTRY(TM) BETA SYSTEM(S) SUPPLIED IS FOR TESTING PURPOSES AND NOT
  INTENDED FOR EVALUATION IN KIMPEN OPERATIONS DURING THE `TEST PERIOD' UNLESS
                            AGREED BY BOTH PARTIES.

      5.1.  The BioSentry(TM) will be installed at a mutually agreed location to
            monitor `treated' water in accordance with the Exhibit B,
            Installation Plan

      5.2.  If desired by Kimpen, the BioSentry(TM) can be installed in parallel
            with a customer supplied standard particle counter and an on-line
            turbidimeter to allow for comparative testing.

      5.3.  JMAR will collect, remove and properly dispose of all biologicals
            used during the set-up of the BioSentry(TM) at Kimpen.

      5.4.  A `spiking receptacle;' will be mounted near the BioSentry(TM) to
            allow for weekly spiking with 8 micron polystyrene spheres and/or
            inactivated Bacteria and Protozoa. JMAR will collect, remove and
            properly dispose of all biologicals used during the `spiking' of the
            BioSentry(TM) at Kimpen.

      5.5.  The BioSentry(TM) system will drain directly to the sewer or other
            protected drain during normal operations.

      5.6.  The BioSentry(TM) will be equipped with a TCP/IP network for
            communications to JMAR's facility

      5.7.  JMAR use of Kimpen's internet connection to remotely monitor the
            operation of the BioSentry(TM).

6. PROGRAM COMPLETION

      Following the 2 month test program, JMAR, will publish a report
      summarizing the test results to Kimpen.

                                       10
<PAGE>

      EXHIBIT A-1

BIOSENTRY(TM) TEST PLAN FOR MONITORING KIMPEN'S TREATED WATER

1. GOAL

      1.1.  To validate the BioSentry(TM) as an Early Warning System for the
            detection and classification of Bacteria and Protozoa

2. EXPERIMENTAL PLAN

      2.1.  The BioSentry(TM) unit will be installed at a location to monitor
            treated water quality. The experiment will occur over a 2 month
            period.

      2.2.  During the initial 2-4 weeks of operation, the BioSentry(TM) will be
            configured for Kimpen's application. Test data obtained during this
            configuration period will not be used as part of the BioSentry(TM)
            system evaluation.

      2.3.  Weekly spiking using 8 micron PSL spheres will occur during the test
            period to identify differences in the performance of the existing
            particle counting monitoring system (if applicable) and the
            BioSentry(TM) system.

            2.3.1.      Concentration level will be 1000 spheres/ml.

            2.3.2.      The number of total event counts observed and False
                        Positives will be recorded

      2.4.  Bi-weekly spiking of UV inactivated Bacteria and Protozoa will occur
            during the test period to track the detection and classification
            accuracy.

            2.4.1.      Concentration level will be 1000 organisms/ml.

            2.4.2.      The number of total event counts observed and False
                        Positives will be recorded

            2.4.3.      The samples will be collected in a Pall Environcheck
                        sampling capsule for delivery to the laboratory.

            2.4.4.      The laboratory will analyze the sample for the
                        background presence of Bacteria and Protozoa using EPA
                        Method 1623 or a similar technique.

      2.5.  Reliability of the BioSentry(TM) unit will be calculated as follows:

            2.5.1.      Hours of operation will be recorded along with any
                        down-time.

            2.5.2.      Down-time duration and reason will be noted.

            2.5.3.      Reliability of the BioSentry(TM) unit will be recorded
                        as % Uptime (Total hours of operation - downtime hours /
                        total hours of operation)

                                       11
<PAGE>

3. FINAL REPORT

      The Final Report will include:

      3.1.  Data obtained from weekly spiking, day-to-day operations (recorded
            events), and reliability will be summarized in the report.

      3.2.  The False Positive Rate (ratio of False Positives recorded to the
            total events recorded) will be calculated.

      3.3.  The classification rate (ratio of properly classified particles to
            the number of particles passing through the BioSentry(TM)) will be
            calculated.

      3.4.  Comparisons of the measured concentrations of test spikes to
            concentrations measured by the `labs'.

      3.5.  Variability of the BioSentry(TM) results will be measured through a
            statistical analysis of the consistency of the results, based on the
            number tests performed.

4. SUCCESSFUL TEST CRITERIA

      The criteria to validate the successful performance of the BioSentry(TM)
      to satisfy Kimpen's needs is stated below. During the initial 2-4 week
      calibration period of operation, this critieria may be changed to reflect
      data obtained during the calibration period.

      4.1.  Pathogen Classification Accuracy: Correctly classifies organism as
            Bacteria or Protozoa 90% of time in concentrates of at least 1000
            organisms/Ml

      4.2.  Event Detection: During the first 2-4 weeks of operation after
            installation, a standard will be created to determine the
            statistical actual versus theoretical yield using polystyrene
            spheres. The results of these tests will produce the expected
            statistical yield of the BioSentry(TM). Successful test results will
            be deemed if the BioSentry(TM) performs within 3 sigma of the
            experimental mean.

      4.3.  Reliability: System uptime of at least 90% during the 2-month test
            duration

      4.4.  False positives: < 10% for bacteria or protozoa classification

      4.5.  Pathogen Classification Repeatability: Two systems are needed to
            obtain this metric. Hence, the criteria for this metric will be
            detailed prior to the start of the 2-system factory tests.

                                       12